06.03.2025 |
Management Team, News

BioStock interview with CEO John Glasspool on VMX-C001 at BioCapital Europe

Related items

16.09.2025

News

VarmX partners with CSL in a strategic collaboration and option agreement to develop novel investigational coagulation treatment
Full funding of VMX-C001 Phase 3 trial, late-stage product development, manufacturing and pre-launch activitiesVarmX shareholders to receive initial $117m upfront…
Read more

03.09.2025

News

VarmX receives FDA Fast Track Designation for lead asset VMX-C001
Designation recognises potential of VMX-C001 to address an unmet need in the restoration of coagulation to enable hemostasis in patients…
Read more